The research results showed that compared with Luminal A type patients, the risk of death from cancer in Luminal B type (HR=1.32, 95% CI: 0.77 to 2.28), HER2 overexpressing (HR=2.03, 95% CI: 1.10 to 3.77), and Triple negative (HR=2.43, 95% CI: 1.36 to 4.36) patients were higher. Here, ERBB2 is linked to cancer.